A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers
Status:
RECRUITING
Trial end date:
2027-03-30
Target enrollment:
Participant gender:
Summary
Unresectable BTC represents an area of unmet medical need due to its very aggressive nature, limited treatment options, and poor prognosis. This study is to evaluate the efficacy and safety of adding TTF to the established regimen of durvalumab plus GemCis for the treatment of patients with previously untreated, unresectable BTC.
Phase:
NA
Details
Lead Sponsor:
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd